Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of August 2024, with a specific reporting date of August 12, 2024. The document addresses the company's regulatory status regarding its listing on The Nasdaq Stock Market.
Key Financial Metrics
The filing does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is exclusively focused on a corporate governance and listing compliance matter.
Material Changes
The primary material change reported is the restoration of compliance with Nasdaq Listing Rule 5550(a)(2). On August 8, 2024, Nasdaq notified Evogene that it regained compliance after its ordinary shares maintained a closing bid price of $1.00 or greater for 10 consecutive business days. Consequently, the prior bid price deficiency matter is now considered closed.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or discussion of operational risks beyond the resolution of the specific listing deficiency. The document references a press release (Exhibit 99.1) announcing the restored compliance.
Investor Verification Checklist
- Verify the current trading price of Evogene shares to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the press release (Exhibit 99.1) for any additional context regarding the stock price movement.
- Confirm that no other Nasdaq listing deficiencies exist that were not addressed in this filing.